Immunogenicity

In drug discovery and development pipelines, measuring immunogenicity—or the body’s ability to produce an immune response—is a critical step. During vaccine development, a strong immune response indicates that protection against an infectious disease has been achieved. In biotherapeutic development, however, signs of immunogenicity suggest the production of anti-drug antibodies, which may lead to adverse events or limit the drug’s effectiveness.

Traditional immunogenicity characterization methods involve ELISAs and electrochemiluminescence assays. Often, these assays are deployed in a tiered strategy, which tends to be time-consuming and expensive. The use of multiple assays also increases the likelihood of unreliable results due to repeated freeze/thaw cycles and frequent sample handling.

Multiplex immunoassays can overcome these obstacles, saving time and costs while preserving sample volume and delivering high-confidence results.

Compared to traditional immunoassays or nucleic acid arrays, xMAP^® bead-based assays are run entirely in a liquid medium—not having to interact with solid-phase substrates makes bead-based multiplexing ideal for rapid reaction times.

By simultaneously detecting up to 500 analytes per well, xMAP^® Technology expands your research by delivering exceptional throughput in addition to high sensitivity and specificity.

You not only save on reagents and precious samples but using an automated workflow significantly reduces hands-on time, making it a cinch to study multiple isotypes of antibodies in a single run.